April 3, 2025
MoonLake Immunotherapeutics, a clinical-stage biotechnology firm headquartered in Zug, Switzerland, has made significant strides in its financing strategy by securing up to $500 million in non-dilutive capital from Hercules Capital, Inc. This agreement, announced on April 3, 2025, positions MoonLake to accelerate its innovative therapies aimed at tackling inflammatory diseases, a market of increasing urgency and potential.Hercules Capital, a well-regarded leader in tailored debt financing specifically directed at life sciences and technology sectors, will provide an initial draw of $75 million upon closing the agreement. The remaining capital will be made available in later tranches, contingent upon the fulf...
April 24, 2024
SAN MATEO, Calif. - Hercules Capital, a leading provider of growth capital to innovative entrepreneurs, is celebrating a significant milestone as it reaches $20.0 billion in cumulative debt commitments. This achievement comes as the company commemorates its 20th year in the industry. Since its inception in 2003, Hercules Capital has remained committed to its mission of providing alternative sources of growth capital to complement institutional financing for growth-stage companies.Hercules Capital s Journey:Hercules Capital was founded with a simple yet ambitious vision: to empower entrepreneurs with access to the necessary funds for their ventures to thrive. Over the past two decades, the company has diligen...
Sources:
Hercules Capital Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Hercules Capital Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
